Specifications
Immunogen
B-lymphoblastoid cell line ARH 77.
Applications
Application Notes
Flow Cyt Use 10μl for 106 cells.
Target
Alternative Names
CD86; CD86 molecule; CD28LG2, CD86 antigen (CD28 antigen ligand 2, B7 2 antigen); T-lymphocyte activation antigen CD86; B lymphocyte antigen B7 2; B7 2; B7.2; BU63; FUN-1; CTLA-4 counter-receptor B7.2; B-lymphocyte activation antigen B7-2; CD86 antigen (
Product Background
Antigen Description
Receptor involved in the costimulatory signal essential for T-lymphocyte proliferation and interleukin-2 production, by binding CD28 or CTLA-4. May play a critical role in the early events of T-cell activation and costimulation of naive T-cells, such as deciding between immunity and anergy that is made by T-cells within 24 hours after activation. Isoform 2 interferes with the formation of CD86 clusters, and thus acts as a negative regulator of T-cell activation.
Pathway
Adaptive Immune System, organism-specific biosystem; Allograft rejection, organism-specific biosystem; Allograft rejection, conserved biosystem; Autoimmune thyroid disease, organism-specific biosystem; Autoimmune thyroid disease, conserved biosystem; CD28 co-stimulation, organism-specific biosystem; CD28 dependent PI3K/Akt signaling, organism-specific biosystem;
Citations
Have you cited DCABH-3051 in a publication?
Let us know and earn a reward for your research.
| Product Name |
Cat. No. |
Applications |
Host Species |
Datasheet |
Price |
Add to Basket |
O'Day, SJ; Hamid, O; et al. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4) - A novel strategy for the treatment of melanoma and other malignancies. CANCER 110:2614-2627(2007).
Wang, J; Lu, JL; et al. Total coumarins from Urtica dentata Hand prevent murine autoimmune diabetes via suppression of the TLR4-signaling pathways. JOURNAL OF ETHNOPHARMACOLOGY 146:379-392(2013).
PDF
Certificate of Analysis
